Tirzepatide

CHEMBL4297839 Phase 4 Approved Protein
Half-Life
5 days
Bioavailability
Protein Binding
Molecular Weight
4813.0 g/mol
LogP
-6.8
Phase
4

Two incretin receptor systems are engaged simultaneously by tirzepatide, a first-in-class dual agonist at the glucose-dependent insulinotropic polypeptide and GLP-1 receptors, sometimes described as a twincretin. Activating both enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite through hypothalamic pathways. Approvals cover type 2 diabetes and obesity, where glycaemic control and weight loss exceed those achieved with GLP-1 receptor agonism alone, and investigation extends to heart failure with preserved ejection fraction, sleep apnoea and fatty liver disease. An elimination half-life of about five days permits weekly administration. The peptide has the formula C225H348N48O68 and a mass near 4813 g/mol.

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist (twincretin) that activates both incretin receptor systems to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic pathways. It is approved for type 2 diabetes and obesity, showing superior glycemic control and weight loss compared to GLP-1 receptor agonists alone, and is under investigation for heart failure with preserved ejection fraction, sleep apnea, and fatty liver disease. Its novel dual incretin action represents a significant advance in metabolic disease pharmacotherapy.

Molecular Weight

4813.0000 g/mol

LogP

-6.80

TPSA

1790.00 Ų

Lipinski RO5

Fail

Therapeutic Areas

Drug Classes

Mechanism of Action

Dual GIP and GLP-1 receptor agonist.

Pharmacokinetics (PK)

Half-Life 5 days

Pharmacodynamics (PD)

Mechanism

Dual GIP and GLP-1 receptor agonist.

SMILES

CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N

InChI

InChI=1S/C225H348N48O68/c1-23-126(10)183(264-198(311)146(64-50-52-88-226)246-202(315)157(109-180(297)298)252-199(312)152(103-124(6)7)261-223(337)225(21,22)269-217(330)185(128(12)25-3)266-209(322)163(120-278)257-200(313)153(107-138-74-78-141(282)79-75-138)250-203(316)158(110-181(299)300)253-207(320)162(119-277)259-216(329)187(134(18)280)267-206(319)155(106-136-60-44-41-45-61-136)254-215(328)186(133(17)279)262-174(289)114-237-193(306)147(83-87-179(295)296)260-222(336)224(19,20)268-192(305)143(227)104-137-72-76-140(281)77-73-137)214(327)242-131(15)190(303)244-148(80-84-168(228)283)196(309)245-145(65-51-53-89-231-175(290)121-340-100-99-339-97-91-233-176(291)122-341-101-98-338-96-90-232-170(285)86-82-150(221(334)335)243-171(286)70-46-38-36-34-32-30-28-26-27-29-31-33-35-37-39-47-71-178(293)294)195(308)240-130(14)191(304)248-154(105-135-58-42-40-43-59-135)205(318)263-182(125(8)9)212(325)247-149(81-85-169(229)284)197(310)251-156(108-139-111-234-144-63-49-48-62-142(139)144)201(314)249-151(102-123(4)5)204(317)265-184(127(11)24-2)213(326)241-129(13)189(302)236-112-172(287)235-115-177(292)270-92-54-66-164(270)210(323)258-161(118-276)208(321)256-160(117-275)194(307)238-113-173(288)239-132(16)218(331)272-94-56-68-166(272)220(333)273-95-57-69-167(273)219(332)271-93-55-67-165(271)211(324)255-159(116-274)188(230)301/h40-45,48-49,58-63,72-79,111,123-134,143,145-167,182-187,234,274-282H,23-39,46-47,50-57,64-71,80-110,112-122,226-227H2,1-22H3,(H2,228,283)(H2,229,284)(H2,230,301)(H,231,290)(H,232,285)(H,233,291)(H,235,287)(H,236,302)(H,237,306)(H,238,307)(H,239,288)(H,240,308)(H,241,326)(H,242,327)(H,243,286)(H,244,303)(H,245,309)(H,246,315)(H,247,325)(H,248,304)(H,249,314)(H,250,316)(H,251,310)(H,252,312)(H,253,320)(H,254,328)(H,255,324)(H,256,321)(H,257,313)(H,258,323)(H,259,329)(H,260,336)(H,261,337)(H,262,289)(H,263,318)(H,264,311)(H,265,317)(H,266,322)(H,267,319)(H,268,305)(H,269,330)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,334,335)

Molecular Formula

C225H348N48O68

HBD / HBA

58 / 70

Rotatable Bonds

163

Heavy Atoms

341

No targets recorded

Target interaction data is not yet available for this drug.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist (twincretin) that activates both incretin receptor systems to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic pathways. It is approved for type 2 diabetes and obesity, showing superior glycemic control and weight loss compared to GLP-1 receptor agonists alone, and is under investigation for heart failure with preserved ejection fraction, sleep apnea, and fatty liver disease. Its novel dual incretin action …

Dual GIP and GLP-1 receptor agonist.

Key pharmacokinetic parameters for Tirzepatide: Half-life: 5 days.

Yes, Tirzepatide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297839. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 168009818. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.